Abstract
Background: The visualization of the subthalamic nucleus (STN) on magnetic resonance imaging (MRI) is variable. Studies of the contribution of patient-related factors and intrinsic brain volumetrics to STN visualization have not been reported previously. Objective: To assess the visualization of the STN during deep brain stimulation (DBS) surgery in a clinical setting. Methods: Eighty-two patients undergoing pre-operative MRI to plan for STN DBS for Parkinson disease were retrospectively studied. The visualization of the STN and its borders was assessed and scored by 3 independent observers using a 4-point ordinal scale (from 0 = not seen to 3 = excellent visualization). This measure was then correlated with the patients’ clinical information and brain volumes. Results: The mean STN visualization scores were 1.68 and 1.63 for the right and left STN, respectively, with a good interobserver reliability (intraclass correlation coefficient: 0.744). Older age and decreased white matter volume were negatively correlated with STN visualization (p < 0.05). Conclusion: STN visualization is only fair to good on routine MRI with good concordance of interindividual rating. Advancing age and decreased white matter are associated with poor visualization of the STN. Knowledge about factors contributing to poor visualization of the STN could alert a surgeon to modify the imaging strategy to optimize surgical targeting.
Journal Section:
Editor's choice
References
1.
Abosch A, Yacoub E, Ugurbil K, Harel N: An assessment of current brain targets for deep brain stimulation surgery with susceptibility-weighted imaging at 7 tesla. Neurosurgery 2010; 67: 1745–1756; discussion 1756.
[PubMed]
2.
Slavin KV, Thulborn KR, Wess C, Nersesyan H: Direct visualization of the human subthalamic nucleus with 3T MR imaging. AJNR Am J Neuroradiol 2006; 27: 80–84.
[PubMed]
3.
Cho ZH, Min HK, Oh SH, Han JY, Park CW, Chi JG, Kim YB, Paek SH, Lozano AM, Lee KH: Direct visualization of deep brain stimulation targets in Parkinson disease with the use of 7-tesla magnetic resonance imaging. J Neurosurg 2010; 113: 639–647.
[PubMed]
4.
Liu T, Eskreis-Winkler S, Schweitzer AD, Chen W, Kaplitt MG, Tsiouris AJ, Wang Y: Improved subthalamic nucleus depiction with quantitative susceptibility mapping. Radiology 2013; 269: 216–223.
[PubMed]
5.
Chandran AS, Bynevelt M, Lind CR: Magnetic resonance imaging of the subthalamic nucleus for deep brain stimulation. J Neurosurg 2016; 124: 96–105.
[PubMed]
6.
Bonneville F, Welter ML, Elie C, du Montcel ST, Hasboun D, Menuel C, Houeto JL, Bonnet AM, Mesnage V, Pidoux B, Navarro S, Cornu P, Agid Y, Dormont D: Parkinson disease, brain volumes, and subthalamic nucleus stimulation. Neurology 2005; 64: 1598–1604.
[PubMed]
7.
Nagahama H, Suzuki K, Shonai T, Aratani K, Sakurai Y, Nakamura M, Sakata M: Comparison of magnetic resonance imaging sequences for depicting the subthalamic nucleus for deep brain stimulation. Radiol Phys Technol 2015; 8: 30–35.
[PubMed]
8.
Manjon JV, Coupe P: volBrain: an online MRI brain volumetry system. Front Neuroinform 2016; 10: 30.
[PubMed]
9.
Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, Dostrovsky JO: Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 1995; 346: 1383–1387.
[PubMed]
10.
Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420–428.
[PubMed]
11.
Cicchetti DV: Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994; 6: 284–290.
12.
Plummer M: rjags: Bayesian graphical models using MCMC. R package version 2.2.0-3. 2011. http://CRAN.R-project.org/package= rjags.
13.
Plummer M: JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), Vienna, March 20–22, 2003.
14.
R Core Team: R: a language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2017. https://www.R-project.org/.
15.
Richter EO, Hoque T, Halliday W, Lozano AM, Saint-Cyr JA: Determining the position and size of the subthalamic nucleus based on magnetic resonance imaging results in patients with advanced Parkinson disease. J Neurosurg 2004; 100: 541–546.
[PubMed]
16.
Daniluk S, Davies K, Ellias SA, Novak P, Nazzaro JM: Assessment of the variability in the anatomical position and size of the subthalamic nucleus among patients with advanced Parkinson’s disease using magnetic resonance imaging. Acta Neurochir (Wien) 2010; 152: 201–210; discussion 210.
[PubMed]
17.
Brass SD, Chen NK, Mulkern RV, Bakshi R: Magnetic resonance imaging of iron deposition in neurological disorders. Topics Magn Reson Imag 2006; 17: 31–40.
[PubMed]
18.
Dormont D, Ricciardi KG, Tande D, Parain K, Menuel C, Galanaud D, Navarro S, Cornu P, Agid Y, Yelnik J: Is the subthalamic nucleus hypointense on T2-weighted images? A correlation study using MR imaging and stereotactic atlas data. AJNR Am J Neuroradiol 2004; 25: 1516–1523.
[PubMed]
19.
Durif F, Pollak P, Hommel M, Ardouin C, Le Bas JF, Crouzet G, Perret J: Relationship between levodopa-independent symptoms and central atrophy evaluated by magnetic resonance imaging in Parkinson’s disease. Eur Neurol 1992; 32: 32–36.
[PubMed]
20.
Alegret M, Junque C, Pueyo R, Valldeoriola F, Vendrell P, Tolosa E, Mercader JM: MRI atrophy parameters related to cognitive and motor impairment in Parkinson’s disease. Neurologia 2001; 16: 63–69.
[PubMed]
21.
Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, Kwon DY: Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol 2011; 32: 682–687.
[PubMed]
22.
Cerasa A, Fasano A, Morgante F, Koch G, Quattrone A: Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. Front Neurol 2014; 5: 49.
[PubMed]
23.
Zonenshayn M, Rezai AR, Mogilner AY, Beric A, Sterio D, Kelly PJ: Comparison of anatomic and neurophysiological methods for subthalamic nucleus targeting. Neurosurgery 2000; 47: 282–292; discussion 292–284.
[PubMed]
24.
Thani NB, Bala A, Swann GB, Lind CR: Accuracy of postoperative computed tomography and magnetic resonance image fusion for assessing deep brain stimulation electrodes. Neurosurgery 2011; 69: 207–214; discussion 214.
[PubMed]
25.
Hamani C, Richter EO, Andrade-Souza Y, Hutchison W, Saint-Cyr JA, Lozano AM: Correspondence of microelectrode mapping with magnetic resonance imaging for subthalamic nucleus procedures. Surg Neurol 2005; 63: 249–253; discussion 253.
[PubMed]
26.
Starr PA: Placement of deep brain stimulators into the subthalamic nucleus or globus pallidus internus: technical approach. Stereotact Funct Neurosurg 2002; 79: 118–145.
[PubMed]
27.
Starr PA, Vitek JL, DeLong M, Bakay RA: Magnetic resonance imaging-based stereotactic localization of the globus pallidus and subthalamic nucleus. Neurosurgery 1999; 44: 303–313; discussion 313–304.
[PubMed]
28.
Ishimori T, Nakano S, Mori Y, Seo R, Togami T, Masada T, Kusuhara T, Ohkawa M, Nagao S, Yamashita Y, Sugiura S: Preoperative identification of subthalamic nucleus for deep brain stimulation using three-dimensional phase sensitive inversion recovery technique. Magn Reson Med Sci 2007; 6: 225–229.
[PubMed]
29.
Hariz MI, Krack P, Melvill R, Jorgensen JV, Hamel W, Hirabayashi H, Lenders M, Wesslen N, Tengvar M, Yousry TA: A quick and universal method for stereotactic visualization of the subthalamic nucleus before and after implantation of deep brain stimulation electrodes. Stereotact Funct Neurosurg 2003; 80: 96–101.
[PubMed]
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.
